Pre-exposure prophylaxis, or PrEP, is a pill taken once daily to prevent HIV infection in uninfected people. When taken consistently, PrEP has been shown to reduce the risk of HIV infection in people who are at high risk by up to 92%. Last year, the US Public Health Service released the first comprehensive clinical practice guidelines for PrEP based on evidence from clinical trials. But how does the prescription and management of PrEP translate into real-world clinical practice?
Kevin Ard, MD, MPH, presents case studies that illustrate clinical challenges in caring for patients eligible for PrEP, and discusses controversies regarding PrEP management.